CARSGEN-B Shares Surge Over 12% Following Strong Annual Revenue Growth and Inclusion in Stock Connect

Stock News03-10

CARSGEN-B (02171) rose more than 12%, extending its recent gains. At the time of writing, the stock was up 10.78% to HK$15.42, with a turnover of HK$127 million. The company recently released its annual results, reporting revenue of RMB 126 million, a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. The group's revenue primarily came from its product, CT053 (an autologous BCMA CAR-T cell therapy). Notably, revenue for CT053 was calculated based on ex-factory prices rather than end-market prices. On March 9, CARSGEN-B was officially included in the Hong Kong Stock Connect scheme. This inclusion reflects market recognition of the company's core CAR-T business development potential, operational compliance, and stock liquidity, aligning with its long-term development strategy and the fundamental interests of all shareholders. The move is expected to provide mainland investors with more convenient access to the stock, significantly enhancing market attention and liquidity, and injecting strong momentum into the company's capital market development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1118317633?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1118317633","market":"us","top_or_hot":-1,"title":"CARSGEN-B Shares Surge Over 12% Following Strong Annual Revenue Growth and Inclusion in Stock Connect","media":"Stock News","content":"<p>CARSGEN-B (02171) rose more than 12%, extending its recent gains. At the time of writing, the stock was up 10.78% to HK$15.42, with a turnover of HK$127 million. The company recently released its annual results, reporting revenue of RMB 126 million, a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. The group's revenue primarily came from its product, CT053 (an autologous BCMA CAR-T cell therapy). Notably, revenue for CT053 was calculated based on ex-factory prices rather than end-market prices. On March 9, CARSGEN-B was officially included in the Hong Kong Stock Connect scheme. This inclusion reflects market recognition of the company's core CAR-T business development potential, operational compliance, and stock liquidity, aligning with its long-term development strategy and the fundamental interests of all shareholders. The move is expected to provide mainland investors with more convenient access to the stock, significantly enhancing market attention and liquidity, and injecting strong momentum into the company's capital market development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CARSGEN-B Shares Surge Over 12% Following Strong Annual Revenue Growth and Inclusion in Stock Connect</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCARSGEN-B Shares Surge Over 12% Following Strong Annual Revenue Growth and Inclusion in Stock Connect\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-10 10:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CARSGEN-B (02171) rose more than 12%, extending its recent gains. At the time of writing, the stock was up 10.78% to HK$15.42, with a turnover of HK$127 million. The company recently released its annual results, reporting revenue of RMB 126 million, a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. The group's revenue primarily came from its product, CT053 (an autologous BCMA CAR-T cell therapy). Notably, revenue for CT053 was calculated based on ex-factory prices rather than end-market prices. On March 9, CARSGEN-B was officially included in the Hong Kong Stock Connect scheme. This inclusion reflects market recognition of the company's core CAR-T business development potential, operational compliance, and stock liquidity, aligning with its long-term development strategy and the fundamental interests of all shareholders. The move is expected to provide mainland investors with more convenient access to the stock, significantly enhancing market attention and liquidity, and injecting strong momentum into the company's capital market development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1585","symbol_name":"昨日强势股","start_time":0,"source_url":"","article_id":"1118317633","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1118317633","pubTimestamp":1773109461,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CARSGEN-B (02171) rose more than 12%, extending its recent gains. At the time of writing, the stock was up 10.78% to HK$15.42, with a turnover of HK$127 million. The company recently released its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1585":"昨日强势股","BK1161":"生物科技","02171":"科济药业-B","BK4588":"碎股","VXUS":"国际股票ETF-Vanguard","BK1587":"次新股","BK1574":"生物医药B类股","BK4585":"ETF&股票定投概念"},"translate_title":"年营收强劲增长并纳入沪股通后，科济源-B股价飙升逾12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02171":1,"VXUS":1},"content_text":"CARSGEN-B (02171) rose more than 12%, extending its recent gains. At the time of writing, the stock was up 10.78% to HK$15.42, with a turnover of HK$127 million. The company recently released its annual results, reporting revenue of RMB 126 million, a year-on-year increase of 218.7%. The loss attributable to owners of the parent narrowed by 87.7% to RMB 97.861 million. The group's revenue primarily came from its product, CT053 (an autologous BCMA CAR-T cell therapy). Notably, revenue for CT053 was calculated based on ex-factory prices rather than end-market prices. On March 9, CARSGEN-B was officially included in the Hong Kong Stock Connect scheme. This inclusion reflects market recognition of the company's core CAR-T business development potential, operational compliance, and stock liquidity, aligning with its long-term development strategy and the fundamental interests of all shareholders. The move is expected to provide mainland investors with more convenient access to the stock, significantly enhancing market attention and liquidity, and injecting strong momentum into the company's capital market development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1118317633","isCrawlerRequest":true}